



## OPEN ACCESS

## EDITED BY

Jian-Hua Liu,  
South China Agricultural University, China

## REVIEWED BY

Liang-xing Fang,  
South China Agricultural University, China  
Juan Li,  
Chinese Academy of Sciences, China  
Dandan He,  
Henan Agricultural University, China

## \*CORRESPONDENCE

Xinan Jiao  
✉ jiao@yzu.edu.cn  
Jing Wang  
✉ wj1231@yzu.edu.cn

†These authors have contributed equally to this work

RECEIVED 08 March 2023

ACCEPTED 26 April 2023

PUBLISHED 19 May 2023

## CITATION

Sun L, Sun G-Z, Jiang Y, Mei C-Y, Wang Z-Y, Wang H-Y, Kong G-M, Jiao X and Wang J (2023) Low prevalence of mobilized resistance genes *bla*<sub>NDM</sub>, *mcr-1*, and *tet(X4)* in *Escherichia coli* from a hospital in China. *Front. Microbiol.* 14:1181940. doi: 10.3389/fmicb.2023.1181940

## COPYRIGHT

© 2023 Sun, Sun, Jiang, Mei, Wang, Wang, Kong, Jiao and Wang. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Low prevalence of mobilized resistance genes *bla*<sub>NDM</sub>, *mcr-1*, and *tet(X4)* in *Escherichia coli* from a hospital in China

Lin Sun<sup>1,2†</sup>, Guo-Zhuang Sun<sup>3†</sup>, Yue Jiang<sup>1,2†</sup>, Cai-Yue Mei<sup>1</sup>, Zhen-Yu Wang<sup>1,2</sup>, Han-Yun Wang<sup>1,2</sup>, Gui-Mei Kong<sup>4</sup>, Xinan Jiao<sup>1,2\*</sup> and Jing Wang<sup>1,2\*</sup>

<sup>1</sup>Jiangsu Key Laboratory of Zoonosis/Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, Yangzhou, China, <sup>2</sup>Key Laboratory of Prevention and Control of Biological Hazard Factors (Animal Origin) for Agrifood Safety and Quality, Ministry of Agriculture of China, Yangzhou University, Yangzhou, China, <sup>3</sup>Department of Clinical Laboratory, Xuyi People's Hospital, Huai'an, China, <sup>4</sup>Medical School of Yangzhou University, Yangzhou University, Yangzhou, China

The emergence and spread of carbapenemase genes, colistin resistance genes *mcr-1*, and tigecycline resistance gene *tet(X)* represent a significant threat to clinical therapy and public health. In this study, we investigated the presence of carbapenemase genes, *mcr-1*, and *tet(X)* in 298 *Escherichia coli* strains obtained from a teaching hospital in China. In total, eight (2.68%), six (2.01%), and one (0.34%) *E. coli* isolates carried *bla*<sub>NDM</sub>, *mcr-1*, and *tet(X4)*, respectively. The *bla*<sub>NDM</sub> gene was located on IncX3 ( $n = 4$ ), F2:A-:B- ( $n = 3$ ), and F2:A1:B1 ( $n = 1$ ) plasmids, with high similarity to multiple plasmids belonging to the same incompatibility type from Enterobacteriaceae. Six MCR-producing strains contained *mcr-1*-carrying IncI2 plasmids, organized similarly to other *mcr-1*-bearing IncI2 plasmids from animals in China. The *bla*<sub>CTX-M-55/64/132/199</sub> gene located within a typical transposition unit (ISEcp1-*bla*<sub>CTX-M-55/64/132/199</sub>-orf477 $\Delta$ ) was inserted near *dnaJ* to generate 5-bp direct repeats in four *mcr-1*-positive plasmids. The *tet(X)* and another four resistance genes [*aadA2*, *tet(A)*, *floR*, and  $\Delta$ *lnu(F)*] were co-located on an IncX1 plasmid, highly similar to other *tet(X4)*-carrying IncX1 plasmids from *Escherichia* and *Klebsiella* of animal or food origin, except that the conjugative transfer region of IncX1 plasmids was absent in our plasmid. Although a low prevalence of *bla*<sub>NDM</sub>, *mcr-1*, and *tet(X)* was observed in *E. coli* from patients in this study, their dissemination associated with some successful pandemic plasmids is of great concern. The continued surveillance of these crucial resistance genes in patients should be strengthened.

## KEYWORDS

carbapenem, colistin, tigecycline, patients, plasmid

## Introduction

Globally, multidrug-resistant (MDR) bacteria are rapidly increasing, which poses a serious threat to clinical therapy and public health (WHO, 2014). In 2019, six pathogens were responsible for 3.57 million deaths associated with antimicrobial resistance, with *Escherichia coli* as the leading pathogen (Antimicrobial Resistance Collaborators, 2022).

Carbapenems are the mainstream antimicrobial agents for treating severe infections caused by MDR Gram-negative pathogens (Wu et al., 2019). However, the emergence and global spread of carbapenem-resistant Enterobacteriaceae (CRE) have become a severe challenge in healthcare settings, particularly for New Delhi metallo- $\beta$ -lactamase (NDM)-producing strains (Wu et al., 2019). *Escherichia coli* is one of the predominant carriers of *bla*<sub>NDM</sub>; some lineages, such as ST167, ST410, and ST617, and popular plasmids (IncX3, IncFII, and IncC) are associated with *bla*<sub>NDM</sub> global dissemination in *E. coli* (Wu et al., 2019).

Colistin and tigecycline are used as last-resort antimicrobial agents for treating severe infections caused by MDR Gram-negative pathogens, especially CRE (Liu et al., 2016; Yaghoubi et al., 2022). However, the identification of novel plasmid-mediated colistin resistance gene *mcr-1* and tigecycline resistance gene *tet(X4)* in *E. coli* from pigs in China can reduce the clinical efficacy of these agents (Liu et al., 2016; He et al., 2019). Since the discovery of *mcr-1*, it has been reported in *E. coli* isolates from different sources worldwide, particularly from food animals. It has been frequently associated with epidemic plasmids (e.g., IncI2, IncX4, and IncHI2) (Nang et al., 2019). The *tet(X4)* gene has recently been increasingly reported in *E. coli* from different sources (e.g., animals, food, and humans), mainly in China (He et al., 2019; Fang et al., 2020). Mobile element ISCR2 and various conjugative and mobilizable plasmids, such as IncQ, IncX1, IncFIB, and IncHI1, facilitate the horizontal transfer of *tet(X4)* in *E. coli* (Fang et al., 2020; Aminov, 2021).

A previous study reported the discovery of *mcr*, *tet(X)*, and carbapenemases in human or animal gut microbiomes (Wang et al., 2020a). The spread of *mcr*, *tet(X)*, and carbapenemases is worrisome, as options for therapy are limited. Therefore, there is an urgent need for evaluating and monitoring the prevalence of pathogenic bacteria carrying *mcr*, *tet(X)*, and carbapenemases. In this study, we investigated the prevalence and characterization of mobilized resistance genes *tet(X4)*, *mcr-1*, and *bla*<sub>NDM</sub> in *E. coli* strains isolated from a teaching hospital in Jiangsu Province, China.

## Materials and methods

### Bacterial isolates and detection of *tet(X)*, *mcr-1*, and carbapenemase genes

From November 2019 to November 2021, 298 non-duplicate *E. coli* strains were isolated from patients in a teaching hospital in Jiangsu Province, China. The presence of *tet(X)*, *mcr-1*, and carbapenemase genes (*bla*<sub>NDM</sub>, *bla*<sub>KPC</sub>, *bla*<sub>IMP</sub>, *bla*<sub>VIM</sub>, and *bla*<sub>OXA-48</sub>) was detected by PCR and sequencing according to previously described protocols (Poirel et al., 2011; Wang et al., 2018, 2019). The information on patients with *bla*<sub>NDM</sub>/*mcr-1*/*tet(X)*-carrying *E. coli* is described in Supplementary Table 1.

### Antimicrobial susceptibility testing

The *bla*<sub>NDM</sub>/*mcr-1*/*tet(X)*-carrying *E. coli* isolates were tested for susceptibility to 14 antimicrobial agents, namely, ampicillin, cefotaxime, meropenem, gentamycin, amikacin, streptomycin, tetracycline, tigecycline, chloramphenicol,

nalidixic acid, ciprofloxacin, colistin, fosfomycin, and sulfamethoxazole/trimethoprim, by using the agar dilution method or broth microdilution method (limited to colistin and tigecycline). *E. coli* ATCC 25922 was used as the quality control strain. The results were interpreted according to Clinical and Laboratory Standards Institute (CLSI) M100, 30<sup>th</sup> edition (CLSI, 2020). Streptomycin (>16 mg/L) was interpreted according to the epidemiological cutoff values for *E. coli* set by the European Committee on Antimicrobial Susceptibility Testing (EUCAST; [www.eucast.org](http://www.eucast.org)).

## Conjugation assay

Conjugation experiments were performed using *bla*<sub>NDM</sub>/*mcr-1*/*tet(X)*-carrying *E. coli* isolates as donor bacteria and *E. coli* C600 (high-level streptomycin resistance) as the recipient strain following a previously described protocol (Chen et al., 2007). In brief, the donor bacteria and *E. coli* C600 were grown in LB broth up to the logarithmic phase and then mixed in a 1:4 ratio and incubated at 37°C for 18 h. Transconjugants were selected on MacConkey or LB agar plates supplemented with 3,000 mg/L streptomycins and 2 mg/L of meropenem (for *bla*<sub>NDM</sub>), colistin (for *mcr-1*), or tigecycline [for *tet(X)*]. They were further confirmed by detecting the presence of *bla*<sub>NDM</sub>, *mcr-1*, and *tet(X)* using PCR. Transfer frequencies were calculated as the number of transconjugants per recipient. Conjugation experiments were performed at least in triplicate.

## Whole genome sequencing and analysis

Genomic DNA was extracted from all *bla*<sub>NDM</sub>/*mcr-1*/*tet(X)*-carrying *E. coli* isolates using a TIAN amp Bacteria DNA kit (Tiangen, Beijing, China) and sequenced by the Illumina HiSeq platform. The 150 bp pair-end raw reads were trimmed with the NGSQC toolkit v.2.3.3 and assembled into contigs using SPAdes v.3.8.2 (Bankevich et al., 2012). Three *E. coli* isolates, XYE3314 (*bla*<sub>NDM-6</sub>), XYE3783 (*bla*<sub>NDM-5</sub>), and XYE3934 [*tet(X4)*], were sequenced using Nanopore MiniION and assembled with Unicycler version 0.4.9. The remaining *bla*<sub>NDM</sub>/*mcr-1*-carrying plasmid contigs were assembled into a complete plasmid sequence using PCR and Sanger sequencing (Supplementary Table 2) using related plasmids as references by BLAST (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>). The genome sequences were analyzed for multi-locus sequence typing (MLST) and resistance genes using MLST and ResFinder, respectively (<https://cge.food.dtu.dk/services>). Analysis and annotation of all *bla*<sub>NDM</sub>/*mcr-1*/*tet(X4)*-carrying plasmids were performed using the RAST server (Aziz et al., 2008), ISfinder (<https://www-is.biotoul.fr/>), ResFinder, PlasmidFinder (<https://cge.food.dtu.dk/services/PlasmidFinder/>), BLAST, and the Gene Construction Kit 4.5 (Textco BioSoftware, Inc., Raleigh, NC, United States). Blast Ring Image Generator (BRIG) version 0.95 was used to visualize the *bla*<sub>NDM</sub>-carrying plasmid comparisons (Alikhan et al., 2011).

## Phylogenetic analysis of *bla*<sub>NDM</sub>/*mcr-1*/*tet*(X4)-positive *Escherichia coli* strains

The phylogenetic tree of all *bla*<sub>NDM</sub>/*mcr-1*/*tet*(X4)-positive *E. coli* strains and *bla*<sub>NDM</sub>-positive *E. coli* ST167 in this study and the NCBI database was constructed based on core genome single nucleotide polymorphisms (SNPs) using ParSNP v. 1.2 (<https://github.com/marbl/parsnp>), respectively. ChiPlot (<http://chiplot.online/#>) was used to visualize the phylogenetic tree.

## Nucleotide sequence accession number

The genome sequences and *bla*<sub>NDM</sub>/*mcr-1*/*tet*(X4)-carrying plasmids have been deposited in GenBank under accession number PRJNA901528.

## Results and discussion

### Characterization of *bla*<sub>NDM</sub>-positive *E. coli* isolates

The *bla*<sub>NDM</sub> gene has been globally distributed as the third most common carbapenemase-encoding gene (Wu et al., 2019). We detected eight (2.68%) *E. coli* isolates carrying the carbapenemase gene *bla*<sub>NDM-5</sub> ( $n = 7$ ) or *bla*<sub>NDM-6</sub> ( $n = 1$ ) (Table 1). None of the other tested carbapenemase genes were detected in this study. All NDM-producing *E. coli* were resistant to meropenem (MIC  $\geq 8$  mg/L), ampicillin, cefotaxime, gentamicin, tetracycline, chloramphenicol, nalidixic acid, ciprofloxacin, and sulfamethoxazole/trimethoprim (Table 1). Resistance to amikacin, streptomycin, or fosfomycin was observed in three, six, and four *bla*<sub>NDM</sub>-positive strains, respectively. Numerous resistance genes were identified in these *bla*<sub>NDM</sub>-carrying strains, which was consistent with their susceptibility profiles. Eight *bla*<sub>NDM</sub>-positive *E. coli* isolates were assigned to ST156 ( $n = 4$ ), ST167 ( $n = 2$ ), ST361 ( $n = 1$ ), and ST1193 ( $n = 1$ ), respectively (Table 1). *E. coli* ST167 has been a global clone for *bla*<sub>NDM</sub> dissemination (Wu et al., 2019). ST156 has been frequently described as *bla*<sub>NDM-5</sub> carriers in patients and animals in China (Yang et al., 2016; Tang et al., 2019; Lin et al., 2020; Zhang et al., 2022). ST361 has been previously associated with *bla*<sub>NDM-5</sub> in patients worldwide (Park et al., 2020; Chakraborty et al., 2021; Huang et al., 2023). ST1193 has been the dominant ST of carbapenem-sensitive *E. coli* isolates in patients at an intensive care unit in China (Ding et al., 2023). Carbapenem-resistant *E. coli* ST1193, an isolate encoding NDM-5 found in this study, might be a cause for concern due to its ability to acquire carbapenem resistance and the potential to cause a future outbreak in hospitals. All of them could successfully transfer meropenem resistance and *bla*<sub>NDM</sub> to *E. coli* C600 by conjugation at frequencies of  $10^{-6}$  to  $10^{-5}$  transconjugants per recipient (Supplementary Table 3).

The *bla*<sub>NDM</sub> gene was located on IncX3 ( $n = 4$ ), F2:A-:B- ( $n = 3$ ), and F2:A1:B1 ( $n = 1$ ) plasmids (Table 1). The IncX3 plasmids carried only one resistance gene, *bla*<sub>NDM-5</sub>, but the IncFII plasmids also carried some other resistance genes, such as *bla*<sub>TEM-1b</sub>, *aadA2*,

and *dfrA12* (Table 1). Four *bla*<sub>NDM-5</sub>-carrying IncX3 plasmids (pYUXEEH1271-NDM, pYUXEEH1278-NDM, pYUXYEH3520-NDM, and pYUXYEH3521-NDM) were obtained from four ST156 NDM-5-producing *E. coli* strains. These IncX3 plasmids were identical, except that two copies of IS1294 were inserted into the accessory replication gene *bis* and DNA relaxase gene *taxC*, respectively, in pYUXEEH1271-NDM and pYUXEEH1278-NDM (Figure 1A). They were also identical or highly similar to other NDM-producing IncX3 plasmids from Enterobacteriaceae (e.g., *E. coli*, *Enterobacter*, and *Klebsiella*) of animal or human origin (Figure 1A). Two F2:A-:B- plasmids, pYUXYEH933-NDM (82,619 bp) and pYUXYEH944-NDM (82,628 bp), obtained from two ST167 NDM-5-encoding isolates, were highly similar and differed by only one nucleotide and one more 9-bp tandem repeat (CAACAGCCG) in the *traD* gene in pYUXYEH944-NDM (Figure 1B). The *bla*<sub>NDM</sub> gene in isolates XEYH3314 and XEYH3783 was located on F2:A-:B- plasmid pYUXYEH3314-NDM (*bla*<sub>NDM-6</sub>, 93,647 bp) and F2:A1:B1 plasmid pYUXYEH3783-NDM (*bla*<sub>NDM-5</sub>, 168,068 bp). These IncFII plasmids showed high similarity to multiple plasmids belonging to the same incompatibility type from Enterobacteriaceae (e.g., *E. coli*, *K. pneumoniae*, and *Salmonella*) from food-producing animals or humans (Figures 1B, C). These *bla*<sub>NDM</sub>-carrying plasmids shared the same core structure  $\Delta cutA-tat-trpF-ble_{MBL}-bla_{NDM-5/-6}-\Delta IS_{Aba125}$  (Figure 2). IncX3 and IncFII plasmids are major vectors for the global transmission of *bla*<sub>NDM</sub> in Enterobacteriaceae (Wu et al., 2019). Particularly, *bla*<sub>NDM</sub>-carrying IncX3 plasmids have been widely disseminated among *E. coli* strains from patients, food-producing animals, companion animals, food products, and the environment in China (Yang et al., 2016; Wu et al., 2019; Zhang et al., 2019; Cen et al., 2021; Wang et al., 2021; Zhao et al., 2021).

### Characterization of *mcr-1*-carrying *E. coli* isolates

To date, 10 plasmid-mediated *mcr* variants (*mcr-1* to *mcr-10*) have been identified in Enterobacteriaceae from animals, humans, and the environment (Hussein et al., 2021). Among them, *mcr-1* is the most common *mcr* variant worldwide (Hussein et al., 2021). In this study, six (2.01%) *E. coli* strains were positive for the colistin resistance gene *mcr-1*. The prevalence of *mcr-1* is close to 4.2%, which is low, in human clinical isolates worldwide (Bastidas-Caldes et al., 2022). The prevalence of *mcr-1* in *E. coli* was significantly decreased in both animals and humans in China after banning colistin as a growth promoter on 30 April 2017 (Wang et al., 2020b).

All MCR-1-positive strains were resistant to colistin (MIC = 8 mg/L), ampicillin, cefotaxime, nalidixic acid, ciprofloxacin, and some other agents (Table 1). In addition to *mcr-1*, they also carried other clinically important resistance genes, such as *bla*<sub>CTX-M</sub> ( $n = 6$ ), *tet*(A) ( $n = 3$ ), *fosA3* ( $n = 3$ ), and *rmtB* ( $n = 1$ ) (Table 1). The presence of these resistance genes could explain their multi-resistance profiles. Six MCR-1-producing isolates were assigned to five STs (ST88, ST450, ST617, ST2003, and ST4985) (Table 1).

Among them, four *mcr-1*-positive *E. coli* strains could transfer *mcr-1* to *E. coli* C600 by conjugation with frequencies of  $10^{-6}$  to

TABLE 1 Characterization of *bla*<sub>NDM</sub>/*mcr*-1/*tet*(X4)-positive *E. coli* isolates in this study.

Strain <sup>a</sup>	Sources <sup>b</sup>	Sampling Date	MLST	Resistance genes <sup>c</sup>	Resistance patterns <sup>d</sup>	Location <sup>e</sup>	Sequencing platform(s)
XYEH933*	Urine, M	2020/6/18	ST167	<u><i>bla</i><sub>NDM-5</sub>/<i>bla</i><sub>TEM-1b</sub>/<i>bla</i><sub>CTX-M-55</sub>/<u><i>aadA2</i></u>/<i>strAB</i>/<i>rmtB</i>/<i>tet</i>(A)/<i>floR</i>/<i>sul1</i>/<i>sul2</i>/<i>dfrA12</i></u>	AMP/CTX/MEM/GEN/AMI/STR/TET/CHL/NAL/CIP/SXT	F2:A-B-	Illumina
XYEH944*	Urine, M	2020/6/18	ST167	<u><i>bla</i><sub>NDM-5</sub>/<i>bla</i><sub>TEM-1b</sub>/<i>bla</i><sub>CTX-M-55</sub>/<u><i>aadA2</i></u>/<i>strAB</i>/<i>rmtB</i>/<i>tet</i>(A)/<i>floR</i>/<i>sul1</i>/<i>sul2</i>/<i>dfrA12</i></u>	AMP/CTX/MEM/GEN/AMI/STR/TET/CHL/NAL/CIP/SXT	F2:A-B-	Illumina
XYEH1271	Blood, F	2020/8/6	ST156	<i>bla</i> <sub>NDM-5</sub> / <i>bla</i> <sub>TEM-1b</sub> / <i>aph</i> (3')-Ia/ <i>aph</i> (4)-Ia/ <i>aac</i> (3)-Iva/ <i>tet</i> (B)/ <i>floR</i> / <i>fosA3</i> / <i>sul2</i> / <i>dfrA12</i> / <i>mph</i> (A)	AMP/CTX/MEM/GEN/TET/CHL/NAL/CIP/FOS/SXT	IncX3	Illumina
XYEH1278	Blood, M	2020/8/6	ST156	<i>bla</i> <sub>NDM-5</sub> / <i>bla</i> <sub>TEM-1b</sub> / <i>aph</i> (3')-Ia/ <i>aph</i> (4)-Ia/ <i>aac</i> (3)-Iva/ <i>tet</i> (B)/ <i>floR</i> / <i>fosA3</i> / <i>sul2</i> / <i>dfrA12</i> / <i>mph</i> (A)	AMP/CTX/MEM/GEN/TET/CHL/NAL/CIP/ FOS/SXT	IncX3	Illumina
XYEH3314*	Urine, M	2021/6/25	ST361	<u><i>bla</i><sub>NDM-6</sub>/<i>bla</i><sub>TEM-1b</sub>/<i>bla</i><sub>CTX-M-55</sub>/<u><i>aac</i>(3)-IIId/<i>aadA1</i>/<i>aadA2</i>/<i>strAB</i>/<i>rmtB</i>/<i>tet</i>(A)/<i>floR</i>/<i>aac</i>(6')-Ib-cr/<i>qnrB6</i>/<i>sul1</i>/<i>sul2</i>/<i>dfrA12</i>/<i>dfrA27</i>/<i>mph</i>(A)/<i>erm</i>(B)/<i>arr-3</i></u></u>	AMP/CTX/MEM/GEN/AMI/STR/TET/CHL/NAL/CIP/SXT	F2:A-B-	Illumina, Nanopore
XYEH3520*	Urine, M	2021/7/19	ST156	<i>bla</i> <sub>NDM-5</sub> / <i>bla</i> <sub>TEM-1b</sub> / <i>bla</i> <sub>CTX-M-55</sub> / <i>bla</i> <sub>CTX-M-65</sub> / <i>aph</i> (3')-Ia/ <i>aph</i> (4)-Ia/ <i>aac</i> (3)-Iva/ <i>aac</i> (3)-IIId/ <i>strAB</i> / <i>tet</i> (A)/ <i>tet</i> (B)/ <i>floR</i> / <i>fosA3</i> / <i>sul2</i> / <i>dfrA12</i> / <i>dfrA14</i> / <i>mph</i> (A)	AMP/CTX/MEM/GEN/STR/TET/CHL/NAL/CIP/FOS/SXT	IncX3	Illumina
XYEH3521*	Urine, M	2021/7/19	ST156	<i>bla</i> <sub>NDM-5</sub> / <i>bla</i> <sub>TEM-1b</sub> / <i>bla</i> <sub>CTX-M-55</sub> / <i>bla</i> <sub>CTX-M-65</sub> / <i>aph</i> (3')-Ia/ <i>aph</i> (4)-Ia/ <i>aac</i> (3)-Iva/ <i>aac</i> (3)-IIId/ <i>strAB</i> / <i>tet</i> (A)/ <i>tet</i> (B)/ <i>floR</i> / <i>fosA3</i> / <i>sul2</i> / <i>dfrA12</i> / <i>dfrA14</i> / <i>mph</i> (A)	AMP/CTX/MEM/GEN/STR/TET/CHL/NAL/CIP/FOS/SXT	IncX3	Illumina
XYEH3783*	Urine, F	2021/8/31	ST1193	<u><i>bla</i><sub>NDM-5</sub>/<i>bla</i><sub>TEM-1b</sub>/<u><i>aac</i>(3)-IIId/<i>aadA1</i>/<i>aadA2</i>/<i>aadA22</i>/<i>tet</i>(A)/<i>floR</i>/<i>cmlA1</i>/<i>qnrS1</i>/<i>sul3</i>/<i>dfrA12</i></u></u>	AMP/CTX/MEM/GEN/STR/TET/CHL/NAL/CIP/SXT	F2:A1:B1	Illumina, Nanopore
XYEH1135*	Urine, F	2020/7/21	ST4985	<u><i>mcr</i>-1/<i>bla</i><sub>CTX-M-132</sub>/<i>bla</i><sub>OXA-10</sub>/<i>aph</i>(3')-IIa/<i>aadA1</i>/<i>tet</i>(A)/<i>floR</i>/<i>cmlA1</i>/<i>dfrA14</i>/<i>arr-3</i></u>	AMP/CTX/GEN/STR/TET/CHL/NAL/CIP/CL/SXT	IncI2	Illumina
XYEH1313*	Urine, F	2020/8/12	ST450	<u><i>mcr</i>-1/<i>bla</i><sub>CTX-M-55</sub></u>	AMP/CTX/NAL/CIP/CL	IncI2	Illumina
XYEH1459	Blood, F	2020/9/2	ST2003	<i>mcr</i> -1/ <i>bla</i> <sub>CTX-M-199</sub> / <i>bla</i> <sub>CTX-M-14</sub> / <i>bla</i> <sub>TEM-1b</sub> / <i>aac</i> (3)-IIId/ <i>aadA5</i> / <i>strAB</i> / <i>tet</i> (A)/ <i>sul1</i> / <i>sul2</i> / <i>dfrA17</i> / <i>mph</i> (A)	AMP/CTX/GEN/STR/TET/NAL/CIP/CL/SXT	IncI2	Illumina
XYEH2259*	Urine, F	2021/1/13	ST88	<i>mcr</i> -1/ <i>bla</i> <sub>CTX-M-14</sub> / <i>aph</i> (3')-Ia/ <i>aph</i> (4)-Ia/ <i>aac</i> (3)-Iva/ <i>aadA1</i> / <i>aadA2</i> / <i>tet</i> (B)/ <i>floR</i> / <i>cmlA1</i> / <i>oqxAB</i> / <i>fosA3</i> / <i>sul1</i> / <i>sul2</i> / <i>sul3</i> / <i>dfrA12</i>	AMP/CTX/GEN/STR/TET/CHL/NAL/CIP/CL/FOS/SXT	IncI2	Illumina
XYEH2299*	Urine, F	2021/1/20	ST88	<i>mcr</i> -1/ <i>bla</i> <sub>CTX-M-14</sub> / <i>aph</i> (3')-Ia/ <i>aph</i> (4)-Ia/ <i>aac</i> (3)-Iva/ <i>aadA1</i> / <i>tet</i> (B)/ <i>floR</i> / <i>cmlA1</i> / <i>oqxAB</i> / <i>fosA3</i> / <i>sul1</i> / <i>sul2</i> / <i>sul3</i> / <i>dfrA12</i>	AMP/CTX/GEN/STR/TET/CHL/NAL/CIP/CL/FOS/SXT	IncI2	Illumina
XYEH3022	Urine, M	2021/5/16	ST617	<i>mcr</i> -1/ <i>bla</i> <sub>CTX-M-64</sub> / <i>bla</i> <sub>TEM-1b</sub> / <i>aph</i> (3')-Ia/ <i>aph</i> (4)-Ia/ <i>aac</i> (3)-Iva/ <i>aadA2</i> / <i>strAB</i> / <i>rmtB</i> / <i>tet</i> (A)/ <i>floR</i> / <i>fosA3</i> / <i>sul1</i> / <i>sul2</i> / <i>dfrA12</i> / <i>erm</i> (B)/ <i>mph</i> (A)	AMP/CTX/GEN/AMI/STR/TET/CHL/NAL/CIP/CL/FOS/SXT	IncI2	Illumina
XYEH3934	Urine, F	2021/9/19	ST7131	<u><i>bla</i><sub>CTX-M-14</sub>/<i>aadA1</i>/<i>aadA2</i>/<i>strAB</i>/<i>tet</i>(A)/<i>tet</i>(X4)/<i>floR</i>/<i>cmlA1</i>/<i>qnrS1</i>/<i>fosA3</i>/<i>sul3</i>/<i>dfrA12</i>/<i>dfrA14</i>/<i>mef</i>(B)/<i>lnu</i>(F)</u>	AMP/CTX/STR/TET/TIL/CHL/NAL/FOS/SXT	IncX1	Illumina, Nanopore

<sup>a</sup>.\* indicates that the strain could successfully transfer *bla*<sub>NDM</sub>/*mcr*-1 to *E. coli* C600 by conjugation. <sup>b</sup>F, female; M, male. <sup>c</sup>Resistance genes located with *bla*<sub>NDM</sub>, *mcr*-1, or *tet*(X4) on the same plasmid are underlined. Antibiotic resistance genes with >90% sequence homology and coverage are shown. <sup>d</sup>AMP, ampicillin; CTX, cefotaxime; MEM, meropenem; GEN, gentamycin; AMI, amikacin; STR, streptomycin; TET, tetracycline; TIL, tigecycline; CHL, chloramphenicol; NAL, nalidixic acid; CIP, ciprofloxacin; CL, colistin; FOS, fosfomycin; SXT, sulfamethoxazole/trimethoprim. <sup>e</sup>Plasmids carried *bla*<sub>NDM</sub>/*mcr*-1/*tet*(X4).






FIGURE 1 (Continued).





via some successful plasmids such as IncX4, IncI2, and IncHI2 (Bastidas-Caldes et al., 2022).

Notably, four *mcr-1*-bearing plasmids in this study also carried the extended-spectrum β-lactamase gene *bla*<sub>CTX-M</sub> (*bla*<sub>CTX-M-55/64/132/199</sub>) (Table 1). The *bla*<sub>CTX-M</sub> gene, located

within a typical transposition unit (*ISEcp1-bla*<sub>CTX-M-orf477</sub>Δ), was inserted near *dnaJ* to generate 5-bp direct repeats (5'-GAAAA-3') (Figure 3). The co-location of *bla*<sub>CTX-M</sub> would allow for *mcr-1* co-selection under cephalosporins, which have been widely used to treat clinical infections.



XYEH933 and XYEH944, and 13 NDM-5-producing ST167 *E. coli* from China ( $n = 12$ ) and Italy ( $n = 1$ ) were clustered in one clade with a close relationship (Supplementary Figure 2).

## Conclusions

Although a low prevalence of *bla*<sub>NDM</sub>, *mcr-1*, and *tet(X)* was observed in *E. coli* isolates from patients in one hospital in this study, their dissemination in *E. coli* associated with some successful pandemic plasmids (IncX, IncF, and IncI2) is of great concern. Conversely, *E. coli* strains from food or food-producing animals in China show a higher prevalence of *bla*<sub>NDM</sub>, *mcr-1*, and *tet(X)* (He et al., 2019; Zhang et al., 2019; Zhao et al., 2020; Cen et al., 2021). However, the small number of *E. coli* strains detected is a limitation of this study. Plasmids facilitate the rapid and global dissemination of resistance genes in Enterobacteriaceae from various sources. Given that resistant bacteria or plasmids could be transmitted from animals to humans via the food chain, the environment, or close contact, surveillance and control of these medically important resistance genes in patients are warranted and need to be optimized based on the One Health approach.

## Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: <https://www.ncbi.nlm.nih.gov/>, PRJNA901528.

## Author contributions

LS and JW conceived the study. LS, G-ZS, YJ, C-YM, H-YW, and G-MK carried out the experiments. LS, YJ, Z-YW, and JW

analyzed the data. JW wrote the manuscript. XJ revised the manuscript. All authors have read and approved the final version of the manuscript.

## Funding

This study was supported by the fifth phase of the 333 Project Scientific Research Project in Jiangsu Province (BRA2020002), the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), and the 111 Project (D18007).

## Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

## Supplementary material

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fmicb.2023.1181940/full#supplementary-material>

## References

- Alikhan, N. F., Petty, N. K., Ben Zakour, N. L., and Beatson, S. A. (2011). BLAST ring image generator (BRIG): simple prokaryote genome comparisons. *BMC Genomics*. 12:402. doi: 10.1186/1471-2164-12-402
- Aminov, R. (2021). Acquisition and spread of antimicrobial resistance: a *tet(X)* case study. *Int. J. Mol. Sci.* 22:3905. doi: 10.3390/ijms22083905
- Antimicrobial Resistance Collaborators (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet*. 399, 629–655. doi: 10.1016/S0140-6736(21)02724-0
- Aziz, R. K., Bartels, D., Best, A. A., DeJongh, M., Disz, T., Edwards, R. A., et al. (2008). The RAST Server: rapid annotations using subsystems technology. *BMC Genomics*. 9:75. doi: 10.1186/1471-2164-9-75
- Bankevich, A., Nurk, S., Antipov, D., Gurevich, A. A., Dvorkin, M., Kulikov, A. S., et al. (2012). SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. *J. Comput. Biol.* 19, 455–477. doi: 10.1089/cmb.2012.0021
- Bastidas-Caldes, C., de Waard, J. H., Salgado, M. S., Villacís, M. J., Coral-Almeida, M., Yamamoto, Y., et al. (2022). Worldwide prevalence of *mcr*-mediated colistin-resistance *Escherichia coli* in isolates of clinical samples, healthy humans, and livestock—a systematic review and meta-analysis. *Pathogens*. 11:659. doi: 10.3390/pathogens11060659
- Cen, D. J., Sun, R. Y., Mai, J. L., Jiang, Y. W., Wang, D., Guo, W. Y., et al. (2021). Occurrence and transmission of *bla*<sub>NDM</sub>-carrying Enterobacteriaceae from geese and the surrounding environment on a commercial goose farm. *Appl. Environ. Microbiol.* 87:e00087–e00021. doi: 10.1128/AEM.00087-21
- Chakraborty, T., Sadek, M., Yao, Y., Imirzalioglu, C., Stephan, R., Poirer, L., et al. (2021). Cross-border emergence of *Escherichia coli* producing the carbapenemase NDM-5 in Switzerland and Germany. *J. Clin. Microbiol.* 59:e02238–e02220. doi: 10.1128/JCM.02238-20
- Chen, C., Cui, C. Y., Zhang, Y., He, Q., Wu, X. T., Li, G., et al. (2019). Emergence of mobile tetracycline resistance mechanism in *Escherichia coli* strains from migratory birds in China. *Emerg. Microbes Infect.* 8, 1219–1222. doi: 10.1080/22221751.2019.1653795
- Chen, L., Chen, Z. L., Liu, J. H., Zeng, Z. L., Ma, J. Y., and Jiang, H. X. (2007). Emergence of RmtB methylase-producing *Escherichia coli* and *Enterobacter cloacae* isolates from pigs in China. *J. Antimicrob. Chemother.* 59, 880–885. doi: 10.1093/jac/dkm065
- CLSI (2020). Clinical and Laboratory Standards Institute (CLSI). *Performance Standards for Antimicrobial Susceptibility Testing. CLSI Supplement M100, 30th Edn.* Wayne, PA: CLSI.
- Cui, C. Y., Li, X. J., Chen, C., Wu, X. T., He, Q., Jia, Q. L., et al. (2022). Comprehensive analysis of plasmid-mediated *tet(X4)*-positive *Escherichia coli* isolates from clinical settings revealed a high correlation with animals and environments-derived strains. *Sci. Total Environ.* 806:150687. doi: 10.1016/j.scitotenv.2021.150687

- Ding, Y., Zhuang, H., Zhou, J., Xu, L., Yang, Y., He, J., et al. (2023). Epidemiology and genetic characteristics of carbapenem-resistant *Escherichia coli* in Chinese intensive care unit analyzed by whole-genome sequencing: a prospective observational study. *Microbiol. Spectr.* 11:e0401022. doi: 10.1128/spectrum.04010-22
- Fang, L. X., Chen, C., Cui, C. Y., Li, X. P., Zhang, Y., Liao, X. P., et al. (2020). Emerging high-level tigecycline resistance: novel tetracycline destructases spread via the mobile Tet(X). *Bioessays.* 42:e2000014. doi: 10.1002/bies.202000014
- He, T., Wang, R., Liu, D., Walsh, T. R., Zhang, R., Lv, Y., et al. (2019). Emergence of plasmid-mediated high-level tigecycline resistance genes in animals and humans. *Nat. Microbiol.* 4, 1450–1456. doi: 10.1038/s41564-019-0445-2
- Huang, L., Hu, H., Xu, C., Zhou, M., Li, Y., Li, Y., et al. (2023). Characterization of NDM-5-producing *Escherichia coli* strains isolated from pediatric patients with bloodstream infections in a Chinese hospital. *Genes.* 14:520. doi: 10.3390/genes14020520
- Hussein, N. H., Al-Kadmy, I. M. S., Taha, B. M., and Hussein, J. D. (2021). Mobilized colistin resistance (*mcr*) genes from 1 to 10: a comprehensive review. *Mol. Biol. Rep.* 48, 2897–2907. doi: 10.1007/s11033-021-06307-y
- Li, Y., Wang, Q., Peng, K., Liu, Y., Xiao, X., Mohsin, M., et al. (2021). Distribution and genomic characterization of tigecycline-resistant *tet(X4)*-positive *Escherichia coli* of swine farm origin. *Microb. Genom.* 7:000667. doi: 10.1099/mgen.0.000667
- Lin, Y., Yang, L., Lu, L., Wang, K., Li, J., Li, P., et al. (2020). Genomic features of an *Escherichia coli* ST156 strain harboring chromosome-located *mcr-1* and plasmid-mediated *bla<sub>NDM-5</sub>*. *Infect. Genet. Evol.* 85:104499. doi: 10.1016/j.meegid.2020.104499
- Liu, D., Wang, T., Shao, D., Song, H., Zhai, W., Sun, C., et al. (2022). Structural diversity of the ISCR2-mediated rolling-cycle transferable unit carrying *tet(X4)*. *Sci. Total Environ.* 826:154010. doi: 10.1016/j.scitotenv.2022.154010
- Liu, Y. Y., Wang, Y., Walsh, T. R., Yi, L. X., Zhang, R., Spencer, J., et al. (2016). Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. *Lancet Infect. Dis.* 16, 161–168. doi: 10.1016/S1473-3099(15)00424-7
- Mohsin, M., Hassan, B., Martins, W. M. B. S., Li, R., Abdullah, S., Sands, K., et al. (2021). Emergence of plasmid-mediated tigecycline resistance *tet(X4)* gene in *Escherichia coli* isolated from poultry, food and the environment in South Asia. *Sci. Total Environ.* 787:147613. doi: 10.1016/j.scitotenv.2021.147613
- Nang, S. C., Li, J., and Velkov, T. (2019). The rise and spread of *mcr* plasmid-mediated polymyxin resistance. *Crit. Rev. Microbiol.* 45, 131–161. doi: 10.1080/1040841X.2018.1492902
- Park, Y., Choi, Q., Kwon, G. C., and Koo, S. H. (2020). Emergence and transmission of New delhi metallo-beta-lactamase-5-producing *Escherichia coli* sequence type 361 in a tertiary hospital in South Korea. *J. Clin. Lab. Anal.* 34:e23041. doi: 10.1002/jcla.23041
- Poirel, L., Walsh, T. R., Cuvillier, V., and Nordmann, P. (2011). Multiplex PCR for detection of acquired carbapenemase genes. *Diagn. Microbiol. Infect. Dis.* 70, 119–123. doi: 10.1016/j.diagmicrobio.2010.12.002
- Tang, B., Chang, J., Cao, L., Luo, Q., Xu, H., Lyu, W., et al. (2019). Characterization of an NDM-5 carbapenemase-producing *Escherichia coli* ST156 isolate from a poultry farm in Zhejiang, China. *BMC Microbiol.* 19, 82. doi: 10.1186/s12866-019-1454-2
- Wang, J., Huang, X. Y., Xia, Y. B., Guo, Z. W., Ma, Z. B., Yi, M. Y., et al. (2018). Clonal spread of *Escherichia coli* ST93 carrying *mcr-1*-harboring IncN1-IncHI2/ST3 plasmid among companion animals, China. *Front. Microbiol.* 9:2989. doi: 10.3389/fmicb.2018.02989
- Wang, J., Lu, M. J., Wang, Z. Y., Jiang, Y., Wu, H., Pan, Z. M., et al. (2022). Tigecycline-resistant *Escherichia coli* ST761 carrying *tet(X4)* in a pig farm, China. *Front. Microbiol.* 13:967313. doi: 10.3389/fmicb.2022.967313
- Wang, J., Xia, Y. B., Huang, X. Y., Wang, Y., Lv, L. C., Lin, Q. Q., et al. (2021). Emergence of *bla<sub>NDM-5</sub>* in Enterobacteriaceae isolates from companion animals in Guangzhou, China. *Microb. Drug Resist.* 27, 809–815. doi: 10.1089/mdr.2020.0210
- Wang, L., Liu, D., Lv, Y., Cui, L., Li, Y., Li, T., et al. (2019). Novel plasmid-mediated *tet(X5)* gene conferring resistance to tigecycline, eravacycline, and omadacycline in a clinical *Acinetobacter baumannii* isolate. *Antimicrob. Agents Chemother.* 64:e01326–e01319. doi: 10.1128/AAC.01326-19
- Wang, Y., Liu, F., Zhu, B., and Gao, G. F. (2020a). Metagenomic data screening reveals the distribution of mobilized resistance genes *tet(X)*, *mcr* and carbapenemase in animals and humans. *J. Infect.* 80, 121–142. doi: 10.1016/j.jinf.2019.09.003
- Wang, Y., Xu, C., Zhang, R., Chen, Y., Shen, Y., Hu, F., et al. (2020b). Changes in colistin resistance and *mcr-1* abundance in *Escherichia coli* of animal and human origins following the ban of colistin-positive additives in China: an epidemiological comparative study. *Lancet Infect. Dis.* 20, 1161–1171. doi: 10.1016/S1473-3099(20)30149-3
- WHO (2014). *Antimicrobial Resistance: Global Report on Surveillance*. Available online at: <https://www.who.int/publications/i/item/9789241564748>
- Wu, W., Feng, Y., Tang, G., Qiao, F., McNally, A., and Zong, Z. (2019). NDM metallo-β-lactamases and their bacterial producers in health care settings. *Clin. Microbiol. Rev.* 32:e00115–e00118. doi: 10.1128/CMR.00115-18
- Yaghoubi, S., Zekiy, A. O., Krutova, M., Gholami, M., Kouhsari, E., Sholeh, M., et al. (2022). Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review. *Eur. J. Clin. Microbiol. Infect. Dis.* 41, 1003–1022. doi: 10.1007/s10096-020-04121-1
- Yang, R. S., Feng, Y., Lv, X. Y., Duan, J. H., Chen, J., Fang, L. X., et al. (2016). Emergence of NDM-5- and MCR-1-producing *Escherichia coli* clones ST648 and ST156 from a single muscovy duck (*Cairina moschata*). *Antimicrob. Agents Chemother.* 60, 6899–6902. doi: 10.1128/AAC.01365-16
- Yu, R., Chen, Z., Schwarz, S., Yao, H., and Du, X. D. (2022). Mobilization of *tet(X4)* by IS1 family elements in porcine *Escherichia coli* isolates. *Antimicrob. Agents Chemother.* 66:e0159721. doi: 10.1128/AAC.01597-21
- Zhai, W., Wang, T., Yang, D., Zhang, Q., Liang, X., Liu, Z., et al. (2022). Clonal relationship of *tet(X4)*-positive *Escherichia coli* ST761 isolates between animals and humans. *J. Antimicrob. Chemother.* 77, 2153–2157. doi: 10.1093/jac/dkac175
- Zhang, Q., Lv, L., Huang, X., Huang, Y., Zhuang, Z., Lu, J., et al. (2019). Rapid increase in carbapenemase-producing Enterobacteriaceae in retail meat driven by the spread of the *bla<sub>NDM-5</sub>*-carrying IncX3 plasmid in China from 2016 to 2018. *Antimicrob. Agents Chemother.* 63:e00573–e00519. doi: 10.1128/AAC.00573-19
- Zhang, X., Fang, C., Zhang, J., Hua, W., He, R., and Zhou, M. (2022). Carbapenemase- and colistin resistant *Escherichia coli* strains from children in China: high genetic diversity and first report of *bla<sub>NDM-5</sub>*, *bla<sub>CTX-M-65</sub>*, *bla<sub>OXA-10</sub>*, *bla<sub>TEM-1</sub>*, and *mcr-1.1* genes co-occurrence in *E. coli* ST156. *Infect. Drug Resist.* 15, 5315–5320. doi: 10.2147/IDR.S378574
- Zhao, Q., Berglund, B., Zou, H., Zhou, Z., Xia, H., Zhao, L., et al. (2021). Dissemination of *bla<sub>NDM-5</sub>* via IncX3 plasmids in carbapenem-resistant Enterobacteriaceae among humans and in the environment in an intensive vegetable cultivation area in eastern China. *Environ. Pollut.* 273:116370. doi: 10.1016/j.envpol.2020.116370
- Zhao, X., Liu, Z., Zhang, Y., Yuan, X., Hu, M., and Liu, Y. (2020). Prevalence and molecular characteristics of avian-origin *mcr-1*-harboring *Escherichia coli* in Shandong Province, China. *Front. Microbiol.* 11:255. doi: 10.3389/fmicb.2020.00255